Member Info for bubbleshoot

Hey. So after I apparently "complained" to the board yesterday (as Soupdragon_Bagholder stated)... I have had a response from Tim Metcalfe:

Dear Chad

Thank you for your message. As the company progresses the studies and partnering discussions on its lead asset, NXP002, as previously announced, there is unfortunately a limited amount, if anything, that can be announced at this stage. Further announcements will be made as soon as there is something to report and please note 38 days since the announcement of the interim results is a very short period of time in the context of what the company is doing. I can also confirm that there have been no material changes to what has previously been announced, otherwise an announcement would have been made without delay.

Best regards

Tim

Tim Metcalfe

Managing Director

IFC Advisory

I'm only trying to help people on this forum Soup. Given the likes it got, others agree.

A formal request is not a complaint. Have you never been involved in business where there are check ups, scrums, progress updates? I guess not 🤡.

None of those are complaints, but just merely updates, check ins, keeping tabs.

I'll let you know if I receive anything. I have my doubts, but I have my hopes.

I'm still counting the start of June to the end of August as when I'd expect some sort of news.

Has anyone else received any generic responses from them?

Done

###

I am writing as a shareholder in Nuformix plc, having invested in, and holding a significant position in the company.

I would like to formally request an update on the following:

1. The NXP002 partnering process - the March 2026 RNS confirmed due diligence was already underway with both large pharmaceutical and speciality pharma partners. The May 28th Half Year Report referenced data being generated in alignment with partner feedback. It has now been over 38 days since that last communication with no further update provided to shareholders.

2. The status of the out-licensing discussions - given the material use of the £1m placing proceeds specifically to fund data generation for partner due diligence, shareholders have a reasonable expectation of being kept informed of material progress or changes to those discussions.

3. The cash position and timeline - with limited runway, shareholders would benefit from understanding management's current assessment of the expected timeline to a licensing agreement.

I appreciate that negotiations must remain confidential under UK MAR and that the company cannot disclose commercially sensitive information. However, a general update confirming that discussions remain active and on track - or alternatively that circumstances have materially changed, would be entirely appropriate and is reasonably expected by the shareholder base.

The IPF landscape has moved significantly since May 28th. The TETON trials have confirmed inhaled IPF therapy works in Phase 3. Jascayd has received approval in additional markets. The commercial urgency for a combination inhaled therapy has never been greater. Shareholders deserve to know that management is capitalising on this environment.

I would welcome a response at your earliest convenience, and would ask that an investor update be considered in the near term.

We'd better get news soon otherwise I'm knocking on NFX for my £1 million investment in the due diligence.

Realistically though, they can't just shun the market with no news (good or bad).

Due diligence is in play. We'll get some news soon 😎

Here's to a lovely week. We could be, should be, maybe, who knows, RNS territory from now till end of August.

BIO International Convention 2026 starts tomorrow in San Diego. Scott DeWire, the Corporate SVP & Global Head, Business Development & Licensing for Boehringer Ingelheim will be there. Quite a title. Probably irrelevant given due diligence is already going ahead. I can't see if our guy is going there, but you'd of thought so.

Personally he didn't say anything positive or negative. As a director, and I'd imagine the Bio space is fairly close knit, he should be chatting to potential partners etc. It's just a normal thing to do. Hopefully all the work up to this point, including the due diligence will be enough for us to get a partner.

There are a number of potential partners out there, tbh.

https://gulfnews.com/uae/health/uae-first-in-region-to-approve-innovative-pulmonary-fibrosis-treatment-1.500580533

Jascayd is an oral PDE4B inhibitor. NXP002 is an inhaled TGFβ inhibitor. Completely different mechanisms and delivery routes. The May 28th data specifically showed NXP002 works alongside antifibrotics including drugs like Jascayd. If Jascayd alone gives 5.4 extra years imagine what a combination of Jascayd and NXP002 give?

Well there is at least some type of organisation who is "interested" given the due diligence.

We will hear news of this - eventually.

Love you guys. You're keeping this board alive.

I'm just going to add a pump right here. NFX is going to 🚀🚀🚀🚀 between now and end of August. 🚀🚀🚀🚀.

That or it's going to 🥀🥀🥀

Not that I've seen. But their phase 2 data/results might be worth a watch

Dead as.

June to the end of August I'm expecting a bad/good/meh RNS regarding the due diligence.

Great summary WhoWrote.

June - August is my guesstimate as to when we can expect the (good/bad) news.

Maybe he is Starmer.

Careful now, he'll restrict access to LSE.

I think FFX wants LSE to remove the 'Share Chat' functionality, and only wants the Live RNS section.

I bet he's a fun guy at a BBQ. All he does is read out from the source and shoots down anyone who dares to say 'I think'

I'm expecting an announcement regarding the due diligence between June and August tbh - Good or bad.

I guess "global" related partnerships require a fair bit of legal stuff so they can take their time.

😅 what is the point in a 10p sale lol

Just found the below on LinkedIn. Looks like a chum sesh.

Have a good evening peoples xx

🚀 Where is the smart money going in UK Biotech? 🚀

With Cambridge Wide Open Week - A week of life sciences @ the home of life sciences (#CWOW) kicking off next week, the countdown is officially on for our Creative Disruption Forum on Dealmaking & Funding Strategies on Wednesday, 17 June at the Mills & Reeve HQ in Cambridge.

No death-by-powerpoint. No scripted pitches. Just raw, honest, Chatham House-style debate between biotech founders, investors, and pharma partners tackling the realities of scaling and funding innovation today.

We are incredibly proud to bring together a stellar line-up of industry leaders, innovators, and ecosystem enablers to drive the conversation:

💡 Biotech Founders & Leaders pushing frontiers:

Jenny Barnett (Monument Tx)

Susan Hill (Mestag Tx)

Nicki Thompson (TRIMTECH Tx)

David Venables (Laverock Tx)

Toby Wilson Waterworth (Ambrose Healthcare)

Ron (Roni) A. Jortner (Aspire Biosciences)

David Boothe (Exert Tx)

Dan Gooding (Nuformix)

Dmitry Veprintsev 🇬🇧 🇨🇭 (AAB Tx)

David Henderson (Mironid Tx)

Paul Kerr (Finn Tx)

Allan Syms (Sizzle Biotech)

Chandan Seth Nanda (ToxiProofAI)

🤝 Big Pharma, Investment & Growth Experts:

Duncan Young (AstraZeneca)

Martin Rigby (ET Capital)

Stephanie Aldridge (Innovate UK Business Growth)

Prof Steve Cohlan (Anglia Ruskin University)

James FRY (Mills & Reeve)

Steered by our resident thought-leader, Prof Tony Sedgwick, we’ll be breaking down what it actually takes to close deals, manage risk, and secure investment in the current macro environment.

The room is capped to ensure high-impact, intimate networking. If you are a life science founder, executive, or investor looking for genuine peer-to-peer dialogue, you need to be in this room.

📅 When: Wednesday, 17 June 📍 Where: Mills & Reeve HQ, Cambridge

Further details and tickets are available on this Eventbrite link:

https://lnkd.in/eSv45BuV

This #CDF starts at a slightly earlier time than usual of 9 am and finishes at 3.30 pm. Many of us from this CDF will go to the #CWOW Garden Party at Hauxton House which is 4-9 pm, and a few more will be finding a #Cambridge pub at 9 pm to watch the England vs Croatia. What's more, we'll be staying over in #Cambridge ready for our 18 June #CDF on Modern #DrugDiscovery strategies, further details of that is on this link:

https://lnkd.in/eKX3bbXY

Very much looking forward to an informative, engaging, connective and fun time in Cambridge next week, we hope to see you there!??!

#BiotechBuddies #CreativeDisruptionForum #LifeSciences #Biotech #VentureCapital #DrugDiscovery #CambridgeWideOpenWeek #Networking Louise Border